Leaderboards/Systemic Lupus Erythematosus Research

Systemic Lupus Erythematosus Research

Last updated July 15, 2026

Rising Stars

Fresh ink, massive impact

Papers

1

Toward harmonized interpretation of anticardiolipin and anti–β2-glycoprotein I antibody detection for diagnosis of antiphospholipid syndrome using defined level intervals and likelihood ratios: communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies

Journal of Thrombosis and Haemostasis|2024

19 cit.

2

Neutrophil extracellular traps as immunofibrotic mediators in RA-ILD; pilot evaluation of the nintedanib therapy

Frontiers in Immunology|2024

11 cit.

3

“Long-term MRI findings in Ankylosing spondylitis patients treated with TNF inhibitors for a decade”

Rheumatology International|2024

3 cit.

4

POS0677 EFFECTIVENESS OF A MEDITERRANEAN DIET-BASED INTERVENTION IN RHEUMATOID ARTHRITIS PATIENTS: A 3-MONTH PROSPECTIVE STUDY

Annals of the Rheumatic Diseases|2024

3 cit.

5

Development of Morphea Following Treatment with an ADA Biosimilar:A Case Report

Current Rheumatology Reviews|2024

2 cit.

6

Profound Coronary Vasospasm Associated with Intraoperative Ketamine Administration: A Case Report

A&A Practice|2024

1 cit.

7

Comparative transcriptomic meta-analysis reveals elevated TCL1A expression in human circulating immune cells across chronic pain conditions

British Journal of Anaesthesia|2025

1 cit.

8

Implication physiopathologique des plexus choroïdes dans la sclérose en plaques

Pratique Neurologique - FMC|2024

0 cit.

9

AB0072 PROPHYLACTIC EFFICACY OF TIXAGEVIMAB-CILGAVIMAB IN RITUXIMAB-TREATED PATIENTS WITH AUTOIMMUNE RHEUMATIC DISEASES

Annals of the Rheumatic Diseases|2024

0 cit.

10

069 Single-cell analysis reveals distinct subpopulations of T cells and elevated IL-26 and IL-17 levels in palmoplantar pustulosis lesions

Journal of Investigative Dermatology|2024

0 cit.

Emerging Leaders

Drafting the new consensus

Researchers

1

Hofstra University

2

Allen R. Hendricks

The University of Texas Southwestern Medical Center

3

Alessandra Banzato

Sapienza University of Rome

4

Josefina Cortés-Hernández

Vall d'Hebron Hospital Universitari

5

Cliniques Universitaires Saint-Luc

6

Geraldine Cambridge

University College London

7

Robert B. Huizinga

Biological Consulting Services (United States)

8

M. Grace Gordon

University of California, San Francisco

9

Meena Subramaniam

University of California, San Francisco

10

The Ohio State University

Papers

1

Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK

The Lancet|2023

796 cit.

2

B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial

Annals of the Rheumatic Diseases|2022

438 cit.

3

Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis

New England Journal of Medicine|2025

198 cit.

4

Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials

Annals of the Rheumatic Diseases|2022

142 cit.

5

Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials

The Lancet Rheumatology|2022

114 cit.

6

Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus

Annals of the Rheumatic Diseases|2023

68 cit.

7

Update on the Efficacy and Safety Profile of Voclosporin: An Integrated Analysis of Clinical Trials in Lupus Nephritis

Arthritis Care & Research|2022

46 cit.

8

Kidney Outcomes and Preservation of Kidney Function With Obinutuzumab in Patients With Lupus Nephritis: A Post Hoc Analysis of the <scp>NOBILITY</scp> Trial

Arthritis & Rheumatology|2023

46 cit.

9

Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials

Annals of the Rheumatic Diseases|2022

42 cit.

10

Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: a<i>post hoc</i>analysis of the TULIP-1 and TULIP-2 trials

Lara D. Veeken|2022

40 cit.

Current Senior Leaders

Wrote the book, still writing it

Papers

1

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

Arthritis & Rheumatism|1988

19.9k cit.

2

The 1982 revised criteria for the classification of systemic lupus erythematosus

Arthritis & Rheumatism|1982

14.6k cit.

3

International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)

Journal of Thrombosis and Haemostasis|2006

7.1k cit.

4

Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus

Arthritis & Rheumatism|2012

5.3k cit.

5

SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY INDEX

Elsevier eBooks|2007

3k cit.

6

The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis

Arthritis & Rheumatism|1990

2.5k cit.

7

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

The Lancet|2011

2k cit.

8

2019 update of the EULAR recommendations for the management of systemic lupus erythematosus

Annals of the Rheumatic Diseases|2019

2k cit.

9

Systemic Lupus Erythematosus

New England Journal of Medicine|2008

1.6k cit.

10

Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H).

Proceedings of the National Academy of Sciences|1990

1.6k cit.

Reagents for Systemic Lupus Erythematosus Research

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Top Rated

Best all-around

Cell Signaling TechnologyEvidence 65

Acetyl-alpha-Tubulin (Lys40) (D20G3) Rabbit Monoclonal Antibody (SignalFlex™ Alexa Fluor® 350 Conjugate)

Cited in 7 papers

View Evidence →

Cell Signaling TechnologyEvidence 65

Merlin/Ezrin/Radixin/Moesin (D1P8I) Rabbit Monoclonal Antibody

Cited in 7 papers

View Evidence →

Cell Signaling TechnologyEvidence 64

DDX4 (D10C5) Rabbit Monoclonal Antibody

Cited in 5 papers

View Evidence →

🌟 All-Time

Most validated

Innovative ResearchEvidence 72

Mouse Anti-Human CD1a Monoclonal Antibody, Alexa Fluor 488 Conjugated, Clone 143

Cited in 11 papers

View Evidence →

Cell Signaling TechnologyEvidence 65

Phospho-GADS (Thr262) (E8L3B) Rabbit Monoclonal Antibody

Cited in 9 papers

View Evidence →

Cell Signaling TechnologyEvidence 67

DYKDDDDK Tag (D6W5B) Rabbit Monoclonal Antibody (Binds to same epitope as Sigma-Aldrich Anti-FLAG M2 antibody) (SignalFlex™ Alexa Fluor® 350 Conjugate)

Cited in 8 papers

View Evidence →